Is Bortezomib reimbursed by medical insurance?

The original drug Bortezomib (Bortezomib) has been launched in China and has been included in medical insurance. Patients can use the national medical insurance for reimbursement during treatment with this drug. Bortezomib is classified as a proteasome inhibitor. This class of drugs has unique therapeutic mechanisms and is widely used in cancer treatment, especially in the treatment of hematological malignancies. The pharmacological mechanism of action of bortezomib involves inhibition of proteasome function. By interfering with the proteasome, it is able to stop protein degradation inside cancer cells, causing protein accumulation in cancer cells, leading to the cessation of proliferation and eventual death of cancer cells.